NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free MRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$20.16▼$22.1350-Day Range N/A52-Week Range N/AVolume309,811 shsAverage Volume343,815 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$26.29 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsHeadlinesOptions ChainTrendsStock AnalysisAnalyst ForecastsCompetitorsHeadlinesOptions ChainTrends Get Medicis Pharmaceutical alerts: Email Address Medicis Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.0% Upside$26.29 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth15.49%From $2.26 to $2.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsFinance Sector547th out of 875 stocksSecurity & Commodity Brokers, Dealers, Exchanges & Services Industry8th out of 11 stocks 4.5 Analyst's Opinion Consensus RatingMedicis Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicis Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medicis Pharmaceutical's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MRX. Previous Next 0.0 Dividend Strength Dividend YieldMedicis Pharmaceutical does not currently pay a dividend.Dividend GrowthMedicis Pharmaceutical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRX. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Medicis Pharmaceutical this week, compared to 0 articles on an average week.Search Interest2 people have searched for MRX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Medicis Pharmaceutical to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.79% of the stock of Medicis Pharmaceutical is held by insiders.Read more about Medicis Pharmaceutical's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Medicis Pharmaceutical are expected to grow by 15.49% in the coming year, from $2.26 to $2.61 per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners”A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About Medicis Pharmaceutical Stock (NYSE:MRX)Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More Ad Weiss RatingsWhat is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners”A small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. MRX Stock News HeadlinesMay 31 at 2:30 PM | globenewswire.comMarex Group plc to Participate in Upcoming Piper Sandler Global Exchange & FinTech ConferenceMay 29, 2024 | investorplace.comWall Street's New Favorites: 3 Stocks Analysts Are Raving About in MayMay 16, 2024 | globenewswire.comMarex Group plc Announces Full Year 2023 Results and Q1 2024 UpdateMay 15, 2024 | bbc.co.ukThe MediciMay 13, 2024 | globenewswire.comMarex Group plc to Report FY 2023 Results and Q1 2024 Update on May 16, 2024May 10, 2024 | morningstar.comMister Spex SE MRXApril 29, 2024 | investorplace.comWhy Is Marex (MRX) Stock On the Move Today?April 25, 2024 | finance.yahoo.comIPOs Shine Bright in a Tough Day for StocksApril 24, 2024 | reuters.comBritish commodities platform Marex prices US IPO at $1.35 bln valuationApril 24, 2024 | globenewswire.comMarex Group plc Announces Pricing of Initial Public OfferingApril 15, 2024 | globenewswire.comMarex Group plc Announces Launch of Initial Public OfferingDecember 20, 2023 | seekingalpha.comTLPPF Telix Pharmaceuticals LimitedDecember 5, 2023 | finance.yahoo.comPrime Therapeutics announces Ken Bodmer as chief financial officerNovember 1, 2023 | morningstar.comAcelRx Pharmaceuticals Inc ACRXOctober 5, 2023 | finance.yahoo.comPRIME THERAPEUTICS/MAGELLAN RX EXPANDS PARTNERSHIP WITH MHK TO MANAGE MEMBER ENROLLMENT WITH MARKETPROMINENCE TECHNOLOGYMarch 27, 2023 | uk.finance.yahoo.comAnanda Developments Plc - Result of General MeetingMarch 23, 2023 | bizjournals.comBoston Pharmaceuticals NewsMarch 9, 2023 | finanznachrichten.deAnanda Developments Plc - Acquisition of MRX and SubscriptionSeptember 20, 2022 | markets.businessinsider.comXpira Pharmaceuticals Inc. Receives FDA Approval For Psilocybin Trial IND ApplicationAugust 31, 2022 | thestreet.comMedicis to Acquire InamedJanuary 22, 2022 | thestreet.comMedicis Stock Hits New 52-Week High (MRX)January 5, 2022 | investing.comMedicis Pharmaceutical Corp (MRX)See More Headlines Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Security & commodity brokers, dealers, exchanges & services Sub-IndustryN/A Current SymbolNYSE:MRX CUSIPN/A CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployees2,074Year FoundedN/APrice Target and Rating Average Stock Price Target$26.29 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+30.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,820,000Free Float68,134,000Market Cap$1.43 billion OptionableOptionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesRobert Roswell Chai-Onn (Age 44)Executive Vice President, General Counsel, Secretary, Director Howard Bradley Schiller (Age 53)Officer, Director Ryan WeldonOfficer, DirectorKey CompetitorsBGC GroupNASDAQ:BGCStoneX GroupNASDAQ:SNEXForge GlobalNYSE:FRGEGarden StageNASDAQ:GSIWTOP Financial GroupNASDAQ:TOPView All Competitors MRX Stock Analysis - Frequently Asked Questions Should I buy or sell Medicis Pharmaceutical stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicis Pharmaceutical in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRX shares. View MRX analyst ratings or view top-rated stocks. What is Medicis Pharmaceutical's stock price target for 2024? 7 brokerages have issued 12-month price objectives for Medicis Pharmaceutical's shares. Their MRX share price targets range from $24.00 to $33.00. On average, they expect the company's stock price to reach $26.29 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price. View analysts price targets for MRX or view top-rated stocks among Wall Street analysts. When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering on Thursday, April 25th 2024. The company issued 15,384,615 shares at a price of $19.00 per share. When does Medicis Pharmaceutical's quiet period expire? Medicis Pharmaceutical's quiet period expires on Tuesday, June 4th. Medicis Pharmaceutical had issued 15,384,615 shares in its IPO on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. During Medicis Pharmaceutical's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. This page (NYSE:MRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
